Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited announced several strategic moves, including the appointments of Dr. Viranchi Arvindbhai Shah as Director, Shilpa Shah as Company Secretary, and Rajeev Kumar as Chief Financial Officer. The company’s board approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026, granting 4,72,000 options, representing 1% of equity, to eligible employees with a potential discount of up to 50% on the market price. Furthermore, Senores Pharmaceuticals is expanding its international operations by incorporating a wholly-owned subsidiary in Mexico to distribute pharmaceutical products and establishing a subsidiary in Canada, in which it will hold at least 51% ownership, both funded through cash investments. Regulatory approvals will be obtained as required by Mexican and Canadian law.

Senores Pharmaceuticals Limited recently announced several corporate actions, including the appointment of Dr. Viranchi Arvindbhai Shah as a director, who brings extensive experience in the pharmaceutical sector. The company also formally approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), granting 4,72,000 options, representing 1% of fully diluted equity, with a potential discount of up to 50% on the market price. Furthermore, Senores Pharmaceuticals intends to incorporate a wholly-owned subsidiary in Mexico for pharmaceutical product supply and distribution, and plans to establish a subsidiary in Canada with at least 51% ownership, also for pharmaceutical distribution. Both international ventures will require regulatory approvals and involve cash investments.

Senores Pharmaceuticals Limited announced the appointment of Dr. Viranchi Arvindbhai Shah as a Director, bringing extensive experience in pharmaceuticals, policy, and international trade. The company also secured approval for the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), granting 4,72,000 options to eligible employees, representing 1% of existing equity, with a potential discount of up to 50% on the market price. Furthermore, Senores Pharmaceuticals plans to incorporate a wholly-owned subsidiary in Mexico for pharmaceutical supply and distribution, and a subsidiary in Canada with at least 51% ownership, both requiring regulatory approvals and involving cash consideration.

Senores Pharmaceuticals Limited announced several corporate actions, including the appointment of Dr. Viranchi Arvindbhai Shah as an independent director, bringing extensive experience in pharmaceuticals, government policy, and education to the board. The company also approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026, granting 4,72,000 options, representing 1% of the company's equity, to eligible employees with a potential discount of up to 50% on the market price. Furthermore, Senores Pharmaceuticals is planning to incorporate a wholly-owned subsidiary in Mexico and a subsidiary company in Canada, with investments of 100% and 51% or more respectively, to expand its presence in those markets, pending regulatory approvals.

Senores Pharmaceuticals Limited announced several key corporate decisions, including the appointment of Dr. Viranchi Arvindbhai Shah as a Director and Ms. Shivali Shah as Company Secretary, with no related party concerns. The board also approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), granting 4,72,000 options, representing 1% of fully diluted equity, to eligible employees with vesting occurring over 1 to 4 years. Furthermore, the company plans to establish wholly-owned subsidiaries in Mexico and Canada to expand its presence in those pharmaceutical markets, requiring cash investment and adherence to local regulatory approvals. The Canadian subsidiary will be at least 51% owned by Senores Pharmaceuticals, either directly or through its Mexican subsidiary.

Net profit of Senores Pharmaceuticals rose 55.70% to Rs 30.72 crore in the quarter ended June 2026 as against Rs 19.73 crore during the previous quarter ended June 2025. Sales rose 38.30% to Rs 180.21 crore in the quarter ended June 2026 as against Rs 130.30 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales180.21130.30 38 OPM %29.8326.22 - PBDT49.4032.48 52 PBT39.4626.49 49 NP30.7219.73 56 Powered by Capital Market - Live

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 July 2026.

Net profit of Senores Pharmaceuticals rose 77.29% to Rs 31.61 crore in the quarter ended March 2026 as against Rs 17.83 crore during the previous quarter ended March 2025. Sales rose 53.39% to Rs 175.19 crore in the quarter ended March 2026 as against Rs 114.21 crore during the previous quarter ended March 2025. For the full year,net profit rose 96.99% to Rs 115.36 crore in the year ended March 2026 as against Rs 58.56 crore during the previous year ended March 2025. Sales rose 58.85% to Rs 632.63 crore in the year ended March 2026 as against Rs 398.25 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales175.19114.21 53 632.63398.25 59 OPM %27.1117.02 -26.6122.52 - PBDT56.7025.91 119 190.3587.41 118 PBT47.4020.68 129 159.1070.57 125 NP31.6117.83 77 115.3658.56 97 Powered by Capital Market - Live

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Senores Pharmaceuticals, Inc. (SPI), USA, a wholly owned subsidiary of Senores Pharmaceuticals, announced that it has successfully entered into a strategic partnership by executing a formal operating agreement on 02 April 2026. This agreement marks a decisive milestone in Senores' international expansion and its strategic entry into the U.S. government procurement market. The partnership has been formalized through the formation of a joint venture (JV) entity, namely Amerisyn, LLC (Amerisyn). The partnership represents a structural leap for Senores' US operations. Through the establishment of this JV framework, Senores is now strategically positioned to facilitate the supply of its high-quality product portfolio to the U.S. Federal Government, veterans affairs and military supply contracts and leverage specialized credentials to participate in long-term national contracts and government supply tenders.